Hexin Suzhou Pharmaceutical Technology

Beijing Hexin Xunming Pharmaceutical Technology (formerly Hexin Suzhou Pharmaceutical Technology) is a clinical-stage Chinese biotechnology company specializing in the development of targeted radiopharmaceuticals and radionuclide drug conjugates (RDCs) for oncology. Founded in 2020, the company leverages its proprietary SMART technology platform and dual-target molecular design capabilities to create theranostic pairs that integrate cancer diagnosis and targeted radiotherapy. Its lead diagnostic candidate, 68Ga-HX01, is a first-in-class dual-targeting PET tracer engaging both CD13 and integrin alpha-V/beta-3, currently in Phase 2 clinical trials for soft tissue sarcoma. Its therapeutic counterpart, 177Lu-HX02, is undergoing Phase 1 clinical evaluation for advanced malignant solid tumors. Hexin is also developing a robust preclinical pipeline of RDCs targeting FAP, CXCR4, Trop2, and PSMA, alongside alpha-nuclide therapies utilizing lead-212 (212Pb).